(Downloading may take up to 30 seconds. If the slide opens in your browser, select File -> Save As to save it.)

Click on image to view larger version.

Figure 1

Suggested recommendation for biochemical evaluation and monitoring of pituitary dysfunction in patients treated with immunotherapy. $When using anti-CTLA4, anti-PD-(L)1 baseline and if symptoms persist on *2 years of follow-up, **high-dose steroids in patients with critical illness, in patients with severe hyponatremia, severe headache, visual abnormalities from pituitary enlargement and low-dose steroids (e.g. hydrocortisone 20–30 mg/day) with mild symptoms such as fatigue, mild headache. &Should be considered to selected premenopausal women. ACTH, adrenocorticotrophic hormone; FSH, follicle-stimulating hormone; fT4, free thyroxine; LH, luteinizing hormone; mo, months; T3, triiodothyronine; TSH, thyroid-stimulating hormone; WNL, within normal range.

This Article

  1. Endocr Relat Cancer vol. 24 no. 12 T331-T347